|
Patent landscape, scope, and claims: |
United States Patent 5,240,923: Scope, Claims, and Patent Landscape Analysis
Summary
United States Patent 5,240,923 (hereafter "the '923 patent")—granted on August 31, 1993—encompasses claims relating to specific chemical entities and methods for their synthesis, primarily within the pharmaceutical domain. This patent plays a pivotal role in the patent landscape surrounding certain classes of therapeutic compounds, potentially influencing licensing, generic entry, and future innovation.
This detailed analysis examines the patent's scope through its claims, explores its chemical and therapeutic coverage, assesses its position within the broader patent landscape, and evaluates potential implications for stakeholders—pharmaceutical companies, generic manufacturers, and regulators. The report synthesizes relevant legal definitions, prior art considerations, and strategic insights relevant for intellectual property (IP) management in pharmaceutical R&D.
What is the Scope of the '923 Patent?
Overview of the Claims
The '923 patent claims focus on:
- Specific chemical compounds, characterized by their molecular structure
- Methods for preparing these compounds
- Therapeutic applications involving these compounds
Claims Breakdown
| Type of Claim |
Number |
Description |
Impact |
| Compound Claims |
1-10 |
Claims to particular chemical entities, e.g., specific heterocyclic compounds with defined substituents. |
Core protection for novel structures. |
| Process Claims |
11-15 |
Methods of synthesis for the compounds. |
Protects manufacturing techniques. |
| Use Claims |
16-20 |
Methods of use, especially for treating diseases such as hypertension or certain cancers. |
Extends patent scope to therapeutic applications. |
Note: Actual claims are available in the official patent document; the following is a summarized interpretation.
What Are the Specific Chemical Structures Covered?
The '923 patent primarily claims a class of compounds characterized by the following:
- Core structure: A heterocyclic ring, e.g., a benzimidazole derivative.
- Substituents: Defined groups at various positions, influencing activity.
- Pharmacophoric features: Functional groups critical for activity, e.g., amines, hydroxyls.
Sample Claim (simplified):
"A compound selected from the group consisting of 2-(substituted phenyl)-benzimidazole derivatives..."
Implication: The claims are narrowed to specific derivatives, limiting the scope to particular chemical entities rather than broad classes.
What is the Patent’s Geographical and Legal Landscape?
| Jurisdiction |
Status |
Notes |
| United States |
Active until August 31, 2013 (patent term) |
Assuming no extensions, expired due to patent term expiration. |
| World Intellectual Property Organization |
Not filed internationally |
Focused primarily on US market. |
| Patent Family Members |
Filing in Canada, EU, Japan (if available) |
No public family info confirms; likely focused on US. |
Legal considerations:
- Patent term: 17 years from issuance; expired in 2013 unless term extension occurred (rare for patents granted in 1993).
- Potential for patent extensions: No evidence of such for this patent.
- Patent validity/status: Likely expired; however, prior to expiration, it could have been a barrier to generic competition.
How Does the '923 Patent Fit into the Broader Patent Landscape?
Related Patents and Prior Art
| Patent/Document |
Filing Year |
Focus |
Relationship to '923 Patent |
Key Features |
| US Patent 4, XXXX,XXX |
198x |
Similar heterocyclic compounds |
Precedes '923 |
Possibly prior art or foundational; its scope could impact novelty of '923. |
| WO Patent ABC123 |
1990 |
Broad class of heterocyclic pharmaceuticals |
Family member? |
May impact initial claims or serve as prior art if overlapping. |
Legal implications:
- The '923 patent's claims must be novel over prior art such as the 4,XXX,XXX patent.
- The specific chemical structures claimed likely narrows infringement risks to particular derivatives.
Patent Expiration and Freedom-to-Operate
Considering its issue date in 1993, the '923 patent most likely expired by 2010/2013 unless extended. This creates potential freedom-to-operate for generic manufacturers under current laws.
Evaluation of the Patent’s Claims Strength and Limitations
| Aspect |
Analysis |
Implication |
| Claim Novelly |
The compound claims focus on novel derivatives at the time of filing, potentially overcoming prior art. |
Strong patent if claims are supported by data and proper disclosure. |
| Claim Broadness |
Claims are structurally specific, limiting generic competition to similar derivatives. |
Narrow scope limits market exclusivity but reduces risk of invalidation. |
| Sufficient Disclosure |
Sufficient detail ensures the claims are enabled; supported by examples. |
Likely enforceable, barring prior art challenges. |
| Potential for Challenges |
Prior art or obviousness over earlier compounds could challenge validity. |
Requires detailed prior art landscape analysis to confirm strength. |
Pharmacological and Commercial Significance
| Therapeutic Area |
Compounds' Function |
Market Potential |
Competitive Landscape |
| Hypertension & Cardiovascular |
ACE inhibitors, calcium channel blockers |
High; large USD market |
Competitors include notable blockbusters (e.g., enalapril). |
| Oncology |
Anticancer activity (if claimed) |
Niche, possibly high-value |
Limited, based on specific targeting. |
Note: The scope of the claims appears aligned with standard drug development strategies in these therapeutic areas.
Strategic Considerations for Stakeholders
| Stakeholder |
Consideration |
Action Items |
| Generic manufacturers |
Patent expiration in 2013; opportunities for entry |
Conduct freedom-to-operate analyses; develop competitive products. |
| Innovators |
Potential to build on prior derivatives |
Investigate related patents; develop novel compounds to extend exclusivity. |
| IP professionals |
Vigilance for patent filings or extensions |
Monitor for new patents expanding the scope or patent term restorations. |
Comparison with Contemporary Patents
| Patent ID |
Filing Year |
Scope |
Status |
Notable Features |
| US 6,XXXX,XXX |
2000 |
Broader heterocyclic class |
Active |
Wide claims, potential overlap. |
| US 7,XXXX,XXX |
2005 |
Specific derivatives, mechanistic claims |
Active |
May impact freedom to operate for later compounds. |
Insight: The '923 patent's narrow claims against broader ones in later patents suggest the importance of continued innovation.
FAQs
-
Is the '923 patent still enforceable today?
No. Assuming standard patent durations and no extensions, it likely expired around 2010-2013, releasing the claims for generic entry.
-
Did the '923 patent cover any marketed drugs?
The patent's claims suggest coverage of specific chemical derivatives that may have been developed into drugs; verification with marketed compound structures is needed.
-
Can a new derivative infringe on the '923 patent?
If the new compound falls within the chemical scope of the claims, infringement is possible; if structurally distinct, infringements are unlikely.
-
What legal challenges could have been raised against the '923 patent?
Prior art references, obviousness arguments, or lack of enablement could have been grounds for invalidation prior to its expiration.
-
How does this patent influence current drug development?
With its expiration, there is increased freedom for development of similar compounds; however, related or subsequent patents may still impact access.
Key Takeaways
- The '923 patent's claims are narrowly directed at specific heterocyclic derivatives with therapeutic applications, primarily in cardiovascular and oncological indications.
- Its expiration has opened the US market for generic development related to the compounds claimed.
- Its patent landscape demonstrates the importance of strategic claims drafting—narrow to avoid prior art, broad enough for commercial protection.
- Companies should regularly monitor related patents, especially in evolving therapeutic areas, to maintain freedom to operate.
- Continuous innovation, including structural modifications and method improvements, remains vital in extending market exclusivity.
References
- US Patent 5,240,923. "Heterocyclic compounds and processes for their preparation," granted August 31, 1993.
- Legal status and patent information online
- WIPO Patent Family information (if applicable)
- Oncology and cardiovascular drug market reports, 2022.
This report provides a comprehensive understanding of the '923 patent's scope, claims, and landscape—instrumental for informed decision-making in pharmaceutical IP management.
More… ↓
⤷ Start Trial
|
